Senate and House final vote approves US healthcare bill amendments

26 March 2010

A package of amendments to the landmark US health care reform law, which extends coverage to 32 million more Americans, has passed its final Congress vote, despite efforts by Republicans to stop it.

The US House of Representatives backed amendments by 220 votes to 207. The vote was needed after a number of Republican objections. The Senate earlier voted for the package by 56-43. Two points, which Democrats say are minor, were deleted. President Barack Obama has already signed the main bill into law. He will now be able to apply a final signature, which is expected within days.

The UK public broadcaster BBC's Richard Lister in Washington DC says that, in recent days, Democrats have begun to seize back control of the health care argument, and opinion polls suggest that more Americans now believe this reform is a good idea. However, he adds, Republicans are threatening to reform or repeal this legislation should they gain control in the mid-term elections in November.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical